Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept Dosing Study in Japanese RA Patients
NCT00484237Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2007
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of etanercept in rheumatoid arthritis (RA) (2 arms), sponsored by Pfizer. Primary endpoint: Change of DAS28-4ESR scores from baseline at 12 weeks. Started Apr 2007; status: completed.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00484237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00484237.